Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MACK
  • CUSIP: 59032810
Key Metrics:
  • Previous Close: $5.27
  • 50 Day Moving Average: $5.31
  • 200 Day Moving Average: $5.93
  • 52-Week Range: $4.39 - $10.18
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.53
  • P/E Growth: -0.87
  • Market Cap: $687.56M
  • Outstanding Shares: 129,240,000
  • Beta: 1.95
  • Net Margins: -193.54%
  • Return on Assets: -105.60%
  • Debt-to-Equity Ratio: -1.07%
  • Current Ratio: 1.31%
  • Quick Ratio: 1.17%
Additional Links:
Companies Related to Merrimack Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (?)
Ratings Breakdown: 4 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $10.75 (103.98% upside)

Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateFirmActionRatingPrice TargetDetails
10/7/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$5.75View Rating Details
10/5/2016BTIG ResearchReiterated RatingNeutralView Rating Details
8/10/2016Robert W. BairdReiterated RatingNeutral$8.00 -> $7.00View Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$16.00 -> $13.00View Rating Details
8/5/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details
5/20/2016MizuhoReiterated RatingBuy$13.00View Rating Details
12/30/2015Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
8/11/2015Cantor FitzgeraldReiterated RatingBuy$16.00View Rating Details
5/13/2015GuggenheimInitiated CoverageBuy$15.00View Rating Details
(Data available from 10/25/2014 forward)


Earnings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.33)($0.40)$33.35 million$33.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.38)($0.33)$24.16 million$21.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.41)($0.41)$31.73 million$21.42 millionViewListenView Earnings Details
11/9/2015Q315($0.40)($0.38)$14.04 million$16.44 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.21)$17.57 million$36.60 millionViewListenView Earnings Details
5/7/2015($0.30)($0.32)ViewN/AView Earnings Details
2/26/2015Q4($0.23)($0.09)ViewN/AView Earnings Details
11/10/2014($0.12)($0.27)ViewN/AView Earnings Details
8/11/2014($0.32)($0.17)ViewN/AView Earnings Details
5/1/2014Q114($0.30)($0.27)$11.93 million$13.03 millionViewN/AView Earnings Details
2/27/2014($0.29)($0.33)ViewN/AView Earnings Details
11/7/2013($0.34)($0.39)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.28)($0.31)$13.68 million$18.45 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.26)($1.76)$11.77 million$12.58 millionViewN/AView Earnings Details
11/14/2012Q312($1.81)$8.60 million$11.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merrimack Pharmaceuticals (NASDAQ:MACK)
Current Year EPS Consensus Estimate: $-0.98 EPS
Next Year EPS Consensus Estimate: $-0.7 EPS


Dividend History for Merrimack Pharmaceuticals (NASDAQ:MACK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Insider Ownership Percentage: 11.49%
Institutional Ownership Percentage: 66.43%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2016Birgit M SchoeberlInsiderSell50,000$5.50$275,000.00View SEC Filing  
3/17/2016Michael E PorterDirectorBuy5,000$7.20$36,000.00View SEC Filing  
3/15/2016Michael E PorterDirectorBuy5,000$7.65$38,250.00View SEC Filing  
3/8/2016Michael E PorterDirectorBuy10,000$7.09$70,900.00View SEC Filing  
3/3/2016Michael E PorterDirectorBuy15,000$6.39$95,850.00View SEC Filing  
3/1/2016Michael E PorterDirectorBuy20,000$6.11$122,200.00View SEC Filing  
2/29/2016Vivian S LeeDirectorBuy35,000$5.50$192,500.00View SEC Filing  
2/29/2016William M McclementsInsiderBuy2,000$5.72$11,440.00View SEC Filing  
1/5/2016Edward J. StewartinsiderSell4,000$8.00$32,000.00View SEC Filing  
12/1/2015Edward J. StewartinsiderSell5,000$9.33$46,650.00View SEC Filing  
11/2/2015Edward J. StewartinsiderSell6,000$9.42$56,520.00View SEC Filing  
10/16/2015Edward J. StewartinsiderSell1,000$10.00$10,000.00View SEC Filing  
10/2/2015Edward J. StewartinsiderSell5,000$8.20$41,000.00View SEC Filing  
9/1/2015Edward J. StewartinsiderSell6,000$9.88$59,280.00View SEC Filing  
8/21/2015Michael E PorterDirectorBuy5,000$9.76$48,800.00View SEC Filing  
8/17/2015Edward J. StewartinsiderSell6,000$10.49$62,940.00View SEC Filing  
8/14/2015Michael E PorterDirectorBuy13,000$10.54$137,020.00View SEC Filing  
7/20/2015Ulrik B NielsenDirectorSell20,000$10.71$214,200.00View SEC Filing  
7/15/2015Edward J StewartInsiderSell6,000$11.84$71,040.00View SEC Filing  
7/15/2015William A SullivanCFOSell15,000$11.85$177,750.00View SEC Filing  
6/19/2015Ulrik B NielsenDirectorSell40,000$12.02$480,800.00View SEC Filing  
6/18/2015Edward J StewartInsiderSell2,000$12.00$24,000.00View SEC Filing  
6/15/2015Edward J StewartInsiderSell6,000$10.67$64,020.00View SEC Filing  
6/15/2015William A SullivanCFOSell15,000$10.65$159,750.00View SEC Filing  
5/19/2015Ulrik B NielsenDirectorSell40,000$13.04$521,600.00View SEC Filing  
5/13/2015Michael E PorterDirectorBuy8,284$11.79$97,668.36View SEC Filing  
4/20/2015Ulrik B NielsenDirectorSell40,000$12.88$515,200.00View SEC Filing  
4/15/2015Edward J StewartSVPSell8,000$12.79$102,320.00View SEC Filing  
4/15/2015William A SullivanCFOSell15,000$12.87$193,050.00View SEC Filing  
4/13/2015Gordon J FehrDirectorSell20,000$13.00$260,000.00View SEC Filing  
3/24/2015Robert J MulroyCEOSell114,368$11.71$1,339,249.28View SEC Filing  
3/23/2015Robert J MulroyCEOSell10,400$11.69$121,576.00View SEC Filing  
3/20/2015Michael E PorterDirectorBuy5,000$11.77$58,850.00View SEC Filing  
3/19/2015Ulrik B NielsenDirectorSell40,000$11.97$478,800.00View SEC Filing  
3/19/2015William A SullivanCFOSell15,000$11.97$179,550.00View SEC Filing  
3/17/2015Birgit M SchoeberlInsiderSell42,234$12.00$506,808.00View SEC Filing  
3/17/2015Edward J StewartSVPSell8,000$11.95$95,600.00View SEC Filing  
3/17/2015Michael E PorterDirectorBuy1,190$11.77$14,006.30View SEC Filing  
3/16/2015Birgit M SchoeberlInsiderSell20,897$12.00$250,764.00View SEC Filing  
3/16/2015Edward J StewartSVPSell6,000$11.93$71,580.00View SEC Filing  
3/11/2015Michael E PorterDirectorBuy5,000$11.33$56,650.00View SEC Filing  
3/2/2015Michael E PorterDirectorBuy5,000$10.93$54,650.00View SEC Filing  
2/23/2015Ulrik B NielsenDirectorSell20,000$10.91$218,200.00View SEC Filing  
2/20/2015Robert J MulroyCEOSell150,000$10.94$1,641,000.00View SEC Filing  
1/15/2015Edward J StewartSVPSell6,000$11.19$67,140.00View SEC Filing  
12/24/2014William A SullivanCFOSell15,000$10.70$160,500.00View SEC Filing  
12/23/2014Vivian S LeeDirectorBuy20,000$10.23$204,600.00View SEC Filing  
12/18/2014Anthony J SinskeyDirectorSell20,000$10.31$206,200.00View SEC Filing  
12/15/2014Edward J StewartSVPSell6,000$10.63$63,780.00View SEC Filing  
12/8/2014Robert J MulroyCEOSell200,000$9.84$1,968,000.00View SEC Filing  
12/2/2014Michael E PorterDirectorBuy8,000$8.71$69,680.00View SEC Filing  
11/21/2014Michael E PorterDirectorBuy11,909$8.87$105,632.83View SEC Filing  
11/18/2014Edward J StewartSVPSell5,000$8.55$42,750.00View SEC Filing  
11/14/2014Michael E PorterDirectorBuy5,000$8.29$41,450.00View SEC Filing  
11/13/2014Gary L CrockerDirectorBuy14,390$8.47$121,883.30View SEC Filing  
11/12/2014Michael E PorterDirectorBuy40,000$8.37$334,800.00View SEC Filing  
10/23/2014Edward J StewartSVPSell3,000$9.05$27,150.00View SEC Filing  
9/30/2014William A SullivanCFOSell105,282$8.61$906,478.02View SEC Filing  
9/29/2014William A SullivanCFOSell64,404$8.40$540,993.60View SEC Filing  
9/24/2014Edward J StewartSVPSell12,000$8.22$98,640.00View SEC Filing  
6/23/2014Gary L CrockerDirectorBuy36,000$6.84$246,240.00View SEC Filing  
5/20/2014Gary CrockerDirectorBuy4,000$6.69$26,760.00View SEC Filing  
5/19/2014Gary CrockerDirectorBuy9,400$6.68$62,792.00View SEC Filing  
5/16/2014Michael PorterDirectorBuy15,000$6.49$97,350.00View SEC Filing  
5/13/2014Anthony SinskeyDirectorBuy5,000$6.74$33,700.00View SEC Filing  
5/8/2014Michael PorterDirectorBuy10,000$6.59$65,900.00View SEC Filing  
5/7/2014Gary CrockerDirectorBuy4,400$6.77$29,788.00View SEC Filing  
5/6/2014Gary CrockerDirectorBuy17,500$6.89$120,575.00View SEC Filing  
5/5/2014Michael PorterDirectorBuy15,000$6.41$96,150.00View SEC Filing  
5/5/2014Robert MulroyCEOBuy5,000$6.31$31,550.00View SEC Filing  
12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00View SEC Filing  
12/12/2013William McclementsSVPBuy4,000$4.26$17,040.00View SEC Filing  
12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00View SEC Filing  
12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.00View SEC Filing  
12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00View SEC Filing  
12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00View SEC Filing  
12/2/2013William McclementsSVPBuy2,000$4.06$8,120.00View SEC Filing  
11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00View SEC Filing  
11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View SEC Filing  
12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View SEC Filing  
12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View SEC Filing  
12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View SEC Filing  
9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View SEC Filing  
8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Merrimack Pharmaceuticals (NASDAQ:MACK)
News IconInteresting MACK Put And Call Options For June 2017 (NASDAQ:MACK) - October 25 at 11:05 AM logoResearch Reports Coverage on Biotech Stocks -- Merrimack Pharma, Aurinia Pharma, Aegerion Pharma, and TG Therapeutics (NASDAQ:MACK) - October 24 at 11:29 AM logoMerrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : October 24, 2016 (NASDAQ:MACK) - October 24 at 11:29 AM logoMerrimack Pharmaceuticals (MACK) Worth a Look: Stock Up 8.2% (NASDAQ:MACK) - October 24 at 11:29 AM
News IconSizzling Stock Alert – Merrimack Pharmaceuticals, Inc.'s (MACK ... - Hot Stocks Point (NASDAQ:MACK) - October 21 at 9:26 AM logoETF’s with exposure to Merrimack Pharmaceuticals, Inc. : October 19, 2016 (NASDAQ:MACK) - October 19 at 6:22 PM logo16 Stocks Moving In Tuesday's Pre-Market Session - Benzinga (NASDAQ:MACK) - October 19 at 10:59 AM
News IconBiotech Stocks To Put On Your Watch List: Merrimack ... - The Voice Registrar (NASDAQ:MACK) - October 19 at 10:59 AM
News IconScorching Hot Biotech Stocks Tape: Idera Pharmaceuticals, Inc. (IDRA), Merrimack Pharmaceuticals, Inc. (MACK) - The Independent Republic (NASDAQ:MACK) - October 19 at 10:59 AM logoMerrimack's Onivyde Drug Gets EU OK (MACK, SHPG) (NASDAQ:MACK) - October 18 at 5:56 PM logoShire Granted EU Marketing Authorization of Onivyde®, in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-B (NASDAQ:MACK) - October 18 at 11:14 AM logo​Pancreatic cancer drug developed in the Bay State approved in Europe (NASDAQ:MACK) - October 18 at 11:14 AM
News Icon2 Biotech Stocks News And Price Trends: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Sarepta Therapeutics ... - The Voice Registrar (NASDAQ:MACK) - October 17 at 11:03 AM
News IconActive Biotech Stock News: Amgen Inc. (AMGN), Merrimack Pharmaceuticals, Inc. (MACK) - The Independent Republic (NASDAQ:MACK) - October 17 at 11:03 AM
News IconNext Weeks Broker Price Targets For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) (NASDAQ:MACK) - October 16 at 5:50 PM logoMERRIMACK PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K) (NASDAQ:MACK) - October 15 at 10:46 AM logoWill Positive Phase 3 Results Get Merrimack Back on Track? (NASDAQ:MACK) - October 15 at 10:46 AM
News IconBrokers Recommendations on: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - FactsReporter (NASDAQ:MACK) - October 14 at 5:52 PM
News IconActive biotech company shares in the news: Merrimack ... - The Voice Registrar (NASDAQ:MACK) - October 14 at 5:52 PM logoMERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:MACK) - October 14 at 5:52 PM logoMerrimack Pharmaceuticals Rises on Positive Late-Stage Results ... - 24/7 Wall St. (NASDAQ:MACK) - October 13 at 6:06 PM
News IconHot Stock for Investors: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - FactsReporter (NASDAQ:MACK) - October 13 at 6:06 PM
News IconPay Close Attention To These Analyst Ratings Merrimack ... - The Voice Registrar (NASDAQ:MACK) - October 13 at 6:06 PM logoHow Risky Is Merrimack Pharmaceuticals Stock? - Motley Fool (NASDAQ:MACK) - October 13 at 6:06 PM logoHow Risky Is Merrimack Pharmaceuticals Stock? (NASDAQ:MACK) - October 13 at 6:06 PM logoMerrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MACK-US : October 13, 2016 (NASDAQ:MACK) - October 13 at 9:34 AM
News Icon2 Sizzling Hot Biotechnology Stocks: Galena Biopharma, Inc. (GALE), Merrimack Pharmaceuticals, Inc. (MACK) - The Independent Republic (NASDAQ:MACK) - October 12 at 11:15 AM logoCompany Update (NASDAQ:MACK): Merrimack Pharmaceuticals Inc Announces Final Results from ONIVYDE Pivotal ... - Smarter Analyst (NASDAQ:MACK) - October 12 at 11:15 AM
News IconFinal Results of NAPOLI-1 Study Confirm Overall Survival and Progression-Free Survival Benefit for the ONIVYDE® Regimen for ... (NASDAQ:MACK) - October 11 at 6:16 PM
News IconSimplex Trading buys $406156 stake in Merrimack Pharmaceuticals Inc (MACK) (NASDAQ:MACK) - October 11 at 6:16 PM logoMerrimack Pharma Rises on Positive Late-Stage Results (NASDAQ:MACK) - October 11 at 6:16 PM logoWhy Merrimack Pharmaceuticals Inc. Rose 38% in September -- The ... - Motley Fool (NASDAQ:MACK) - October 10 at 5:42 PM logoWhy Merrimack Pharmaceuticals Inc. Rose 38% in September (NASDAQ:MACK) - October 10 at 1:06 PM
News IconActive Run Stocks Logging Brokers' Choice: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Galena Biopharma ... - Street Wise Report (press release) (blog) (NASDAQ:MACK) - October 10 at 10:41 AM
News IconTime To Put On The Watch List? – Merrimack Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:MACK) - October 10 at 10:41 AM logoMerrimack Pharmaceuticals Falls Back To Support Following JPMorgan Downgrade (NASDAQ:MACK) - October 7 at 5:51 PM logoMerrimack Pharma downgraded by JP Morgan (NASDAQ:MACK) - October 7 at 5:51 PM logoMerrimack Pharmaceuticals (MACK) Stock Drops, JPMorgan Downgrades (NASDAQ:MACK) - October 7 at 5:51 PM logo4 Reasons JPMorgan Just Downgraded Merrimack Pharmaceuticals (NASDAQ:MACK) - October 7 at 2:16 PM
News IconStock Dragging Lower Pre-Bell: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - CSZ News (NASDAQ:MACK) - October 7 at 11:04 AM
News IconAnalysts Valuations For Two Stocks: Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Ocwen Financial Corp (NYSE ... - The Voice Registrar (NASDAQ:MACK) - October 7 at 11:04 AM
News IconActive biotech company shares in the news: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), 22nd Century Group ... - The Voice Registrar (NASDAQ:MACK) - October 7 at 11:04 AM logoGastrointestinal Therapeutics and Diagnostics - Technologies and Global Markets - Expected to Reach $63.8 Billion in 2021 - Research and Markets (NASDAQ:MACK) - October 6 at 5:52 PM
News IconStocks fall...Merrimack CEO resigns, company cuts 22 percent of workforce...Bass Pro to acquire rival Cabela's (NASDAQ:MACK) - October 5 at 9:20 AM
News IconBay State cancer drug maker cuts workforce (NASDAQ:MACK) - October 4 at 4:07 PM logoMerrimack Pharmaceuticals Cuts Jobs; CEO Resigns Amid Restructuring Effort (NASDAQ:MACK) - October 4 at 4:07 PM
News IconInvestments Worthy Stocks: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Aratana Therapeutics, Inc. (NASDAQ ... - Street Wise Report (press release) (blog) (NASDAQ:MACK) - October 4 at 10:47 AM
News IconTime To Put On The Watch List? - Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Ophthotech Corporation ... - The Voice Registrar (NASDAQ:MACK) - October 4 at 10:47 AM logoMerrimack Pharmaceuticals CEO resigns as company cuts 22% of workforce - MarketWatch (NASDAQ:MACK) - October 4 at 10:47 AM logoMerrimack Pharmaceuticals Cuts Jobs; CEO Resigns Amid Restructuring Effort - Wall Street Journal (NASDAQ:MACK) - October 4 at 10:47 AM


Merrimack Pharmaceuticals (NASDAQ:MACK) Chart for Tuesday, October, 25, 2016

Last Updated on 10/25/2016 by Staff